0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Bayer Thermo Fisher Collab For Companion Diagnostic Assays
News Feed
course image
  • 22 Mar 2024
  • Admin
  • News Article

Bayer & Thermo Fisher Collab for Companion Diagnostic Assays

Bayer, Thermo Fisher Scientific collaborate to develop NGS-based companion diagnostic assays

Overview

Bayer AG and Thermo Fisher Scientific Inc. announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.

CDx Devdelopment

The CDx will be developed using Thermo Fisher’s Oncomine Dx Express Test on the Ion Torrent Genexus Dx System, a fully integrated NGS platform that can deliver results on a patient’s tumour or liquid biopsy sample in as little as 24 hours.

Words from Bayer

We are committed to developing new treatment options for patients with unmet medical needs, reducing exposure to treatments that are not as likely to provide benefit or can spare them unnecessary side effects,” said Christine Roth, member of the executive committee of Bayer’s Pharmaceuticals Division and Head of the Oncology Strategic Business Unit at Bayer. “The collaboration with Thermo Fisher Scientific perfectly complements Bayer’s precision medicine strategy and fits our ambition to further advance the field of genomic testing and personalized treatment in oncology, providing the right treatment to the right patient at the right time.

Words from Thermo Fisher

We are committed to providing simple and fast next-generation sequencing-based solutions using tumour and liquid biopsy samples that support future access to targeted therapies, thereby helping to improve patient outcomes,” said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “The combination of our experience in developing distributable CDx tests with the game-changing turnaround time offered by our Genexus Dx System, allows clinical teams to quickly gather results to better understand the impact of these therapies. Pairing this with Bayer’s growing precision oncology portfolio, we are well-positioned for the potential to help ensure that eligible patients can be quickly matched with the right treatment.

Financial Terms of the Cooperation Were Not Disclosed

About Thermo Fisher Scientific

  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. 
  • Its Mission is to enable our customers to make the world healthier, cleaner and safer. 
  • Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.

About Bayer

  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. 
  • In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form